Global Information
회사소개 | 문의 | 비교리스트

세계의 신항원 암백신 시장 : 예측과 기회(-2025년)

Global Neoantigen Cancer Vaccine Market By Product, By Neoantigen Type, By Route of Administration, By Cell, By Technology, By Delivery Mechanism, By Application, By Region, Competition, Forecast & Opportunities, 2025

리서치사 TechSci Research
발행일 2020년 05월 상품 코드 938713
페이지 정보 영문 111 Pages
가격
US $ 4,450 ₩ 5,088,000 Unprintable PDF and Excel (Single User License)
US $ 5,450 ₩ 6,231,000 PDF and Excel (Multi-User License)
US $ 9,450 ₩ 10,805,000 PDF and Excel (Custom Research License)

TechSci Research 보고서는 10% Customization 서비스가 포함되어 있습니다. 보고서에 포함돼 있지 않은 리서치 데이터와 시장 동향을 추가적으로 요청할 수 있습니다. 자세한 사항은 문의하여 주시기 바랍니다.



세계의 신항원 암백신 시장 : 예측과 기회(-2025년) Global Neoantigen Cancer Vaccine Market By Product, By Neoantigen Type, By Route of Administration, By Cell, By Technology, By Delivery Mechanism, By Application, By Region, Competition, Forecast & Opportunities, 2025
발행일 : 2020년 05월 페이지 정보 : 영문 111 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 신항원 암백신(Neoantigen Cancer Vaccine) 시장은 예측 기간 중 약 35%의 CAGR로 성장할 것으로 예측되고 있습니다. 시장의 성장에 관여하는 주요 요인은 기술의 급속한 혁신과 의료 부문의 인프라 개발입니다.

세계의 신항원 암백신 시장을 부문별 및 지역별로 조사했으며, 시장 규모 및 시장 점유율 예측, 촉진요인과 과제, 시장 동향, 경쟁 구도, 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 제품 개요

제2장 조사 방법

제3장 개요

제4장 세계의 신항원 암백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 제품별(맞춤형, 시판)
    • 신항원 유형별(핵산, 수지상세포, 종양 세포, SLP/Synthetic long peptide)
    • 투여 경로별(정맥내, 근육내, 경피, 기타)
    • 세포별(자기, 동종)
    • 기술별(전게놈 시퀀스, RNA 시퀀스, HLA 타이핑)
    • 전달 기구별(유전자총, 일렉트로포레이션, 리포솜, 비로솜 등)
    • 용도별(흑색종, 뇌암, 위장, 폐 등)
    • 회사별(2019)
    • 지역별
  • 시장의 매력 지수

제5장 아시아태평양의 신항원 암백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 제품별
    • 신항원 유형별
    • 투여 경로별
    • 셀별
    • 기술별
    • 용도별
    • 국가별
  • 시장의 매력 지수
  • 아시아태평양 : 국가 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 싱가포르
    • 호주

제6장 유럽의 신항원 암백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 제품별
    • 신항원 유형별
    • 투여 경로별
    • 셀별
    • 기술별
    • 용도별
    • 국가별
  • 시장의 매력 지수
  • 유럽 : 국가 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인

제7장 북미의 신항원 암백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 제품별
    • 신항원 유형별
    • 투여 경로별
    • 셀별
    • 기술별
    • 용도별
    • 국가별
  • 시장의 매력 지수
  • 북미 : 국가 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 남미의 신항원 암백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 제품별
    • 신항원 유형별
    • 투여 경로별
    • 셀별
    • 기술별
    • 용도별
    • 국가별
  • 시장의 매력 지수
  • 남미 : 국가 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제9장 중동·아프리카의 신항원 암백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 제품별
    • 신항원 유형별
    • 투여 경로별
    • 셀별
    • 기술별
    • 용도별
    • 국가별
  • 시장의 매력 지수
  • 중동·아프리카 : 국가 분석
    • 남아프리카공화국
    • 사우디아라비아
    • UAE

제10장 시장 역학

  • 촉진요인
  • 과제

제11장 시장 동향과 발전

제12장 경쟁 구도

  • 경쟁 전망
  • 주요 기업의 개요
    • Avidea Technologies
    • Agenus
    • Roche
    • Nouscom
    • Merck
    • Pfizer
    • Advaxis
    • Medigene
    • Genocea Biosciences
    • Gritstone Oncology
    • Gilead Sciences
    • Eli Lilly
    • Novogene
    • Moderna
    • BioNTech
    • Ziopharm
    • ISA Pharmaceutical
    • Vaccibody
    • Brightpath Bio
    • Vaximm

제13장 전략적 권장사항

제14장 면책사항

KSA 20.06.03

Global neoantigen cancer vaccine market is projected to grow at a CAGR of close to 35% during the forecast period. The key factor responsible for the growth of neoantigen cancer vaccine market is rapid innovations in technology as well as infrastructural developments in healthcare sector. Additionally, growing investments by the governing bodies and healthcare providers is another major factor that is anticipated to bode well for the growth of neoantigen cancer vaccine market across the globe in the coming years. Moreover, rising cases of cancers is further anticipated to bolster the market growth through 2025.

The global neoantigen cancer vaccine market is segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, region and company. Based on route of administration, the market can be segmented into intravenous, intramuscular, transdermal and others. Out of which, the intravenous segment dominated the market until 2019 and is further anticipated to be the fastest-growing application segment of the neoantigen cancer vaccine market during the forecast period as well. This growth can be accredited to quick response as well as the to the fact that drug dosage can be controlled easily. Along with that, intramuscular injections can be used rather than intravenous because some drugs cause irritation to veins when injected intravenously. This is expected to result in high growth of intramuscular route of administration segment over the coming years.

Major players operating in the global neoantigen cancer vaccine market include Avidea Technologies, Agenus, Roche, Nouscom, Merck, Pfizer, Advaxis, Medigene, Genocea Biosciences, Gritstone Oncology, Gilead Sciences, Eli Lilly, Novogene, Moderna, BioNTech, Ziopharm, ISA Pharmaceutical, Vaccibody, Brightpath Bio, Vaximm, etc. The companies operating in the market across the globe are focussing more towards expanding their share in the market.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study:

  • To analyse and forecast the market size of global neoantigen cancer vaccine market.
  • To classify and forecast global neoantigen cancer vaccine market based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, company and regional distribution.
  • To identify drivers and challenges for global neoantigen cancer vaccine market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global neoantigen cancer vaccine market.
  • To conduct pricing analysis for global neoantigen cancer vaccine market.
  • To identify and analyse the profile of leading players operating in global neoantigen cancer vaccine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the new products, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global neoantigen cancer vaccine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Neoantigen cancer vaccine manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to neoantigen cancer vaccine
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global neoantigen cancer vaccine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Product:

Personalized neo-antigen vaccine

Off-the shell neoantigen vaccine

  • Market, By Neoantigen Type:

Nucleic acid

Dendritic cell

Tumor cell

Synthetic Long Peptide

  • Market, By Route of Administration:

Intravenous

Intramuscular

Transdermal

Others

  • Market, By Cell:

Autologous

Allogenic

  • Market, By Technology:

Whole Genome Sequencing

RNA Sequencing

HLA Typing

  • Market, By Delivery Mechanism:

Gene gun

Electroporation

Liposomes

Virosomes

Others

  • Market, By Application:

Melanoma

Brain cancer

Gastrointestinal

Lung

Others

  • Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Singapore

Middle East and Africa

  • South Africa
  • Saudi Arabia
  • UAE

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global neoantigen cancer vaccine market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Global Neoantigen Cancer Vaccine Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value & Volume
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product (Personalized neo-antigen vaccine, Off-the shell neoantigen vaccine)
    • 4.2.2. By Neoantigen Type (Nucleic acid, Dendritic cell, Tumor cell and Synthetic long peptide (SLP))
    • 4.2.3. By Route of Administration (Intravenous, Intramuscular, Transdermal, Others)
    • 4.2.4. By Cell (Autologous, Allogenic)
    • 4.2.5. By Technology (Whole Genome Sequencing, RNA Sequencing, HLA Typing)
    • 4.2.6. By Delivery Mechanism (Gene gun, Electroporation, Liposomes, Virosomes and Others)
    • 4.2.7. By Application (Melanoma, Brain cancer, Gastrointestinal, Lung and Others)
    • 4.2.8. By Company (2019)
    • 4.2.9. By Region
  • 4.3. Market Attractiveness Index

5. Asia-Pacific Neoantigen Cancer Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product
    • 5.2.2. By Neoantigen Type
    • 5.2.3. By Route of Administration
    • 5.2.4. By Cell
    • 5.2.5. By Technology
    • 5.2.6. By Application
    • 5.2.7. By Country
  • 5.3. Market Attractiveness Index
  • 5.4. Asia-Pacific: Country Analysis
    • 5.4.1. China Neoantigen Cancer Vaccine Market Outlook
      • 5.4.1.1. Market Size & Forecast
        • 5.4.1.1.1. By Value
      • 5.4.1.2. Market Share & Forecast
        • 5.4.1.2.1. By Product
        • 5.4.1.2.2. By Neoantigen Type
        • 5.4.1.2.3. By Route of Administration
        • 5.4.1.2.4. By Cell
        • 5.4.1.2.5. By Technology
        • 5.4.1.2.6. By Application
    • 5.4.2. India Neoantigen Cancer Vaccine Market Outlook
      • 5.4.2.1. Market Size & Forecast
        • 5.4.2.1.1. By Value
      • 5.4.2.2. Market Share & Forecast
        • 5.4.2.2.1. By Product
        • 5.4.2.2.2. By Neoantigen Type
        • 5.4.2.2.3. By Route of Administration
        • 5.4.2.2.4. By Cell
        • 5.4.2.2.5. By Technology
        • 5.4.2.2.6. By Application
    • 5.4.3. Japan Neoantigen Cancer Vaccine Market Outlook
      • 5.4.3.1. Market Size & Forecast
        • 5.4.3.1.1. By Value
      • 5.4.3.2. Market Share & Forecast
        • 5.4.3.2.1. By Product
        • 5.4.3.2.2. By Neoantigen Type
        • 5.4.3.2.3. By Route of Administration
        • 5.4.3.2.4. By Cell
        • 5.4.3.2.5. By Technology
        • 5.4.3.2.6. By Application
    • 5.4.4. South Korea Neoantigen Cancer Vaccine Market Outlook
      • 5.4.4.1. Market Size & Forecast
        • 5.4.4.1.1. By Value
      • 5.4.4.2. Market Share & Forecast
        • 5.4.4.2.1. By Product
        • 5.4.4.2.2. By Neoantigen Type
        • 5.4.4.2.3. By Route of Administration
        • 5.4.4.2.4. By Cell
        • 5.4.4.2.5. By Technology
        • 5.4.4.2.6. By Application
    • 5.4.5. Singapore Neoantigen Cancer Vaccine Market Outlook
      • 5.4.5.1. Market Size & Forecast
        • 5.4.5.1.1. By Value
      • 5.4.5.2. Market Share & Forecast
        • 5.4.5.2.1. By Product
        • 5.4.5.2.2. By Neoantigen Type
        • 5.4.5.2.3. By Route of Administration
        • 5.4.5.2.4. By Cell
        • 5.4.5.2.5. By Technology
        • 5.4.5.2.6. By Application
    • 5.4.6. Australia Neoantigen Cancer Vaccine Market Outlook
      • 5.4.6.1. Market Size & Forecast
        • 5.4.6.1.1. By Value
      • 5.4.6.2. Market Share & Forecast
        • 5.4.6.2.1. By Product
        • 5.4.6.2.2. By Neoantigen Type
        • 5.4.6.2.3. By Route of Administration
        • 5.4.6.2.4. By Cell
        • 5.4.6.2.5. By Technology
        • 5.4.6.2.6. By Application

6. Europe Neoantigen Cancer Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Neoantigen Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By Cell
    • 6.2.5. By Technology
    • 6.2.6. By Application
    • 6.2.7. By Country
  • 6.3. Market Attractiveness Index
  • 6.4. Europe: Country Analysis
    • 6.4.1. France Neoantigen Cancer Vaccine Market Outlook
      • 6.4.1.1. Market Size & Forecast
        • 6.4.1.1.1. By Value
      • 6.4.1.2. Market Share & Forecast
        • 6.4.1.2.1. By Product
        • 6.4.1.2.2. By Neoantigen Type
        • 6.4.1.2.3. By Route of Administration
        • 6.4.1.2.4. By Cell
        • 6.4.1.2.5. By Technology
        • 6.4.1.2.6. By Application
    • 6.4.2. Germany Neoantigen Cancer Vaccine Market Outlook
      • 6.4.2.1. Market Size & Forecast
        • 6.4.2.1.1. By Value
      • 6.4.2.2. Market Share & Forecast
        • 6.4.2.2.1. By Product
        • 6.4.2.2.2. By Neoantigen Type
        • 6.4.2.2.3. By Route of Administration
        • 6.4.2.2.4. By Cell
        • 6.4.2.2.5. By Technology
        • 6.4.2.2.6. By Application
    • 6.4.3. United Kingdom Neoantigen Cancer Vaccine Market Outlook
      • 6.4.3.1. Market Size & Forecast
        • 6.4.3.1.1. By Value
      • 6.4.3.2. Market Share & Forecast
        • 6.4.3.2.1. By Product
        • 6.4.3.2.2. By Neoantigen Type
        • 6.4.3.2.3. By Route of Administration
        • 6.4.3.2.4. By Cell
        • 6.4.3.2.5. By Technology
        • 6.4.3.2.6. By Application
    • 6.4.4. Italy Neoantigen Cancer Vaccine Market Outlook
      • 6.4.4.1. Market Size & Forecast
        • 6.4.4.1.1. By Value
      • 6.4.4.2. Market Share & Forecast
        • 6.4.4.2.1. By Product
        • 6.4.4.2.2. By Neoantigen Type
        • 6.4.4.2.3. By Route of Administration
        • 6.4.4.2.4. By Cell
        • 6.4.4.2.5. By Technology
        • 6.4.4.2.6. By Application
    • 6.4.5. Spain Neoantigen Cancer Vaccine Market Outlook
      • 6.4.5.1. Market Size & Forecast
        • 6.4.5.1.1. By Value
      • 6.4.5.2. Market Share & Forecast
        • 6.4.5.2.1. By Product
        • 6.4.5.2.2. By Neoantigen Type
        • 6.4.5.2.3. By Route of Administration
        • 6.4.5.2.4. By Cell
        • 6.4.5.2.5. By Technology
        • 6.4.5.2.6. By Application

7. North America Neoantigen Cancer Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Neoantigen Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Cell
    • 7.2.5. By Technology
    • 7.2.6. By Application
    • 7.2.7. By Country
  • 7.3. Market Attractiveness Index
  • 7.4. North America: Country Analysis
    • 7.4.1. United States Neoantigen Cancer Vaccine Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Product
        • 7.4.1.2.2. By Neoantigen Type
        • 7.4.1.2.3. By Route of Administration
        • 7.4.1.2.4. By Cell
        • 7.4.1.2.5. By Technology
        • 7.4.1.2.6. By Application
    • 7.4.2. Mexico Neoantigen Cancer Vaccine Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Product
        • 7.4.2.2.2. By Neoantigen Type
        • 7.4.2.2.3. By Route of Administration
        • 7.4.2.2.4. By Cell
        • 7.4.2.2.5. By Technology
        • 7.4.2.2.6. By Application
    • 7.4.3. Canada Neoantigen Cancer Vaccine Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Product
        • 7.4.3.2.2. By Neoantigen Type
        • 7.4.3.2.3. By Route of Administration
        • 7.4.3.2.4. By Cell
        • 7.4.3.2.5. By Technology
        • 7.4.3.2.6. By Application

8. South America Neoantigen Cancer Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Neoantigen Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Cell
    • 8.2.5. By Technology
    • 8.2.6. By Application
    • 8.2.7. By Country
  • 8.3. Market Attractiveness Index
  • 8.4. South America: Country Analysis
    • 8.4.1. Brazil Neoantigen Cancer Vaccine Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Product
        • 8.4.1.2.2. By Neoantigen Type
        • 8.4.1.2.3. By Route of Administration
        • 8.4.1.2.4. By Cell
        • 8.4.1.2.5. By Technology
        • 8.4.1.2.6. By Application
    • 8.4.2. Argentina Neoantigen Cancer Vaccine Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Product
        • 8.4.2.2.2. By Neoantigen Type
        • 8.4.2.2.3. By Route of Administration
        • 8.4.2.2.4. By Cell
        • 8.4.2.2.5. By Technology
        • 8.4.2.2.6. By Application
    • 8.4.3. Colombia Neoantigen Cancer Vaccine Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Product
        • 8.4.3.2.2. By Neoantigen Type
        • 8.4.3.2.3. By Route of Administration
        • 8.4.3.2.4. By Cell
        • 8.4.3.2.5. By Technology
        • 8.4.3.2.6. By Application

9. Middle East and Africa Neoantigen Cancer Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Neoantigen Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Cell
    • 9.2.5. By Technology
    • 9.2.6. By Application
    • 9.2.7. By Country
  • 9.3. Market Attractiveness Index
  • 9.4. MEA: Country Analysis
    • 9.4.1. South Africa Neoantigen Cancer Vaccine Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Product
        • 9.4.1.2.2. By Neoantigen Type
        • 9.4.1.2.3. By Route of Administration
        • 9.4.1.2.4. By Cell
        • 9.4.1.2.5. By Technology
        • 9.4.1.2.6. By Application
    • 9.4.2. Saudi Arabia Neoantigen Cancer Vaccine Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Product
        • 9.4.2.2.2. By Neoantigen Type
        • 9.4.2.2.3. By Route of Administration
        • 9.4.2.2.4. By Cell
        • 9.4.2.2.5. By Technology
        • 9.4.2.2.6. By Application
    • 9.4.3. UAE Neoantigen Cancer Vaccine Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Product
        • 9.4.3.2.2. By Neoantigen Type
        • 9.4.3.2.3. By Route of Administration
        • 9.4.3.2.4. By Cell
        • 9.4.3.2.5. By Technology
        • 9.4.3.2.6. By Application

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

12. Competitive Landscape

  • 12.1. Competition Outlook
  • 12.2. Players Profiled (Leading Companies)
    • 12.2.1. Avidea Technologies
    • 12.2.2. Agenus
    • 12.2.3. Roche
    • 12.2.4. Nouscom
    • 12.2.5. Merck
    • 12.2.6. Pfizer
    • 12.2.7. Advaxis
    • 12.2.8. Medigene
    • 12.2.9. Genocea Biosciences
    • 12.2.10. Gritstone Oncology
    • 12.2.11. Gilead Sciences
    • 12.2.12. Eli Lilly
    • 12.2.13. Novogene
    • 12.2.14. Moderna
    • 12.2.15. BioNTech
    • 12.2.16. Ziopharm
    • 12.2.17. ISA Pharmaceutical
    • 12.2.18. Vaccibody
    • 12.2.19. Brightpath Bio
    • 12.2.20. Vaximm

13. Strategic Recommendations

14. About Us & Disclaimer

Back to Top
전화 문의
F A Q